Blackrock, INC Schedule 13G passive stakes
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.4% Passive Stake in El Pollo Loco Holdings
BlackRock, Inc. has filed an Amendment No. 9 to Schedule 13G, reporting a 6.4% passive beneficial ownership stake in El Pollo Loco Holdings Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 12 to Schedule 13G, disclosing its beneficial ownership of 8.3% of Verint Systems Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 6.4% of Warby Parker Inc.'s Class A Stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Schedule 13G, Disclosing 7.8% Passive Stake in Zimmer Biomet Holdings Inc.
BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, reporting a 7.8% beneficial ownership stake in Zimmer Biomet Holdings Inc. as of March 31, 2025, held for ordinary course of business purposes.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.7% beneficial ownership stake in AAON INC's common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.5% Stake in Accuray Inc. Common Stock
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.5% beneficial ownership stake in Accuray Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.4% Passive Stake in Alaska Air Group
BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.4% of Alaska Air Group Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 8.1% of Albemarle Corporation's common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.0% Passive Stake in Align Technology Inc.
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 7.0% beneficial ownership stake in Align Technology Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.3% Passive Stake in Allogene Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.3% beneficial ownership stake in Allogene Therapeutics, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Stake in American Electric Power, Disclosing 7.5% Beneficial Ownership
BlackRock, Inc. has filed an amended Schedule 13G, revealing its beneficial ownership of 7.5% of American Electric Power Co Inc's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 11 to Schedule 13G, reporting a 6.9% beneficial ownership stake in American International Group Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.1% beneficial ownership stake in American Superconductor Corp as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 15 to its Schedule 13G, reporting a 7.6% beneficial ownership stake in Amgen Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.2% Passive Stake in AnaptysBio Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.2% beneficial ownership stake in AnaptysBio Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Increases Stake in Anika Therapeutics to 6.8%
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.8% beneficial ownership stake in Anika Therapeutics Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.8% Passive Stake in Elevance Health
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.8% beneficial ownership stake in Elevance Health, Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 9.1% beneficial ownership stake in Arrow Electronics Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, disclosing its beneficial ownership of 8.8% of Bath & Body Works, Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.6% Passive Stake in Boston Scientific Corp
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% passive beneficial ownership stake in Boston Scientific Corp as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 16 to its Schedule 13G, reporting an 8.8% beneficial ownership stake in CMS Energy Corp as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its passive beneficial ownership of 7.4% of Campbell's Co common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.9% Stake in Citizens Financial Group
BlackRock, Inc. has filed an updated Schedule 13G, revealing a beneficial ownership of 8.9% of Citizens Financial Group Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.8% Passive Stake in Otis Worldwide Corp
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.8% beneficial ownership stake in Otis Worldwide Corp's common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.0% Passive Stake in PTC Therapeutics, Inc.
BlackRock, Inc. has filed an amended Schedule 13G, revealing a passive beneficial ownership of 8.0% in PTC Therapeutics, Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 6 to Schedule 13G, reporting a 7.1% beneficial ownership stake in TrueCar Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.3% Passive Stake in Twist Bioscience Corp
BlackRock, Inc. has filed an amended Schedule 13G, revealing a passive beneficial ownership of 8.3% of Twist Bioscience Corp's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 9.2% beneficial ownership stake in UNUM GROUP's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its beneficial ownership of 7.6% of VAXCYTE, Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.5% Stake in Virgin Galactic Holdings
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.5% beneficial ownership stake in Virgin Galactic Holdings, Inc. as of March 31, 2025.